ABVC Profile
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company based in Fremont, California, focuses on developing drugs and medical devices to address unmet medical needs in the United States. The company is advancing a robust pipeline of therapeutic candidates across various stages of clinical development. Among its leading projects is ABV-1501, a combination therapy currently in Phase I/II clinical trials for triple-negative breast cancer. Additionally, ABV-1504 has completed Phase II clinical trials targeting major depressive disorders, and ABV-1505 is in Phase II clinical trials for attention deficit hyperactivity disorder (ADHD).
ABVC BioPharma's diverse portfolio also includes ABV-1703, which has completed Phase I clinical trials for pancreatic cancer treatment, and ABV-1702, which has finished Phase I trials for treating myelodysplastic syndromes. Another key candidate is ABV-1601, in Phase I/II clinical trials, aimed at treating depression in cancer patients. Furthermore, ABV-1701 Vitargus is being developed for the treatment of retinal detachment or vitreous hemorrhage, showcasing the company's commitment to addressing critical medical conditions with innovative therapies.
The company's strategic collaborations play a significant role in its research and development efforts. ABVC BioPharma has a co-development agreement with Rgene Corporation, which enhances its ability to advance its clinical programs. Additionally, collaboration agreements with BioHopeKing Corporation and BioFirst Corporation further bolster its research capabilities and provide access to valuable resources and expertise, facilitating the development of its promising drug candidates.
ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation, benefiting from the parent company's support and resources. The company's mission is to bring novel therapeutic solutions to market, improving the lives of patients with serious health conditions. Through its innovative approach and strategic partnerships, ABVC BioPharma aims to make significant contributions to the biopharmaceutical industry and fulfill its commitment to addressing unmet medical needs.
|
